

Completed Switches to Biosimilars

Drug	Originator (Switch from)	Biosimilar (Switch to)	Indications
Originator Coverage Ends on May 31, 2022			
Insulin aspart	NovoRapid	Trurapi	Diabetes
Originator Coverage Ends on February 28, 2022			
Enoxaparin	Lovenox	Redesca Inclunox Noromby	Prevention and Treatment of Thromboembolic Events
Originator Coverage Ends on November 30, 2021			
Adalimumab	Humira	Idacio Amgevita Hadlima Hyrimoz Hulio	Ankylosing Spondylitis Plaque Psoriasis Psoriatic Arthritis Rheumatoid Arthritis Crohn's Disease Ulcerative Colitis Polyarticular Juvenile Idiopathic Arthritis Hidradenitis Suppurativa Non-Infectious Uveitis
Etanercept	Enbrel	Brenzys Erelzi	Ankylosing Spondylitis Plaque Psoriasis Psoriatic Arthritis Polyarticular Juvenile Idiopathic Arthritis Rheumatoid Arthritis
Infliximab	Remicade	Inflectra Renflexis Avsola	Ankylosing Spondylitis Plaque Psoriasis Psoriatic Arthritis Rheumatoid Arthritis Crohn's Disease Ulcerative Colitis
Insulin glargine	Lantus	Basaglar	Diabetes
Insulin lispro	Humalog	Admelog	Diabetes
Rituximab	Rituxan	Ruxience Truxima Riximyo	Rheumatoid Arthritis Vasculitis Autoimmune Diseases
Glatiramer	Copaxone	Glatect	Multiple Sclerosis